{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG003","lowerLimit":"1.0","upperLimit":"1.0","value":"1.0"}]}],"title":"Complete Response: PCI ≤ 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"}]}],"title":"Partial Response: At least 4 points decrease in PCI"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.8","upperLimit":"100.0","value":"100"},{"groupId":"OG001","lowerLimit":"100.0","upperLimit":"100.0","value":"100"},{"groupId":"OG002","lowerLimit":"100.0","upperLimit":"100.0","value":"100"},{"groupId":"OG003","lowerLimit":"100.0","upperLimit":"100.0","value":"100"}]}],"title":"Stable Disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase for PD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"}]}],"title":"Progressive Disease: At least 4 points increase in PCI"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"description":"Clinicopathologic response by PCI is reported with a 95% confidence interval. Complete Response (CR) is PCI ≤ 5 with negative histology of at least 3 peritoneal biopsies of suspect nodules and washings with negative cytology. Partial Response (PR) is at least 4 points decrease in PCI. Progressive Disease (PD) is at least 4 points increase in PCI. The appearance of one or more new lesions is also considered progression. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the PCI.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ended treatment at the regular dose level: 80 intravenous (IV)/80 Intraperitoneal (IP) + 300 twice a day (BID).","id":"OG000","title":"Intravenous Paclitaxel Dose Level 1, Intraperitoneal Paclitaxel Dose Level 1, Nilotinib Dose Level 1"},{"description":"Had the planned doses for Intraperitoneal (IP) Paclitaxel (80 IP) and by mouth (PO) nilotinib (300 twice a day (BID) but declined to go up to the 80mg/m\\^2 of intravenous (IV) Paclitaxel.","id":"OG001","title":"Intravenous Paclitaxel DoseLevel -1, Intraperitoneal Paclitaxel Dose Level 1, Nilotinib Dose Level 1"},{"description":"Had the planned doses for intravenous (IV) and Intraperitoneal (IP) Paclitaxel (80 IV/80 IP) but had a dose reduction for Nilotinib (400 every day (QD).","id":"OG002","title":"Intravenous Paclitaxel DoseLevel 1, Intraperitoneal Paclitaxel Dose Level 1, Nilotinib Dose Level -1"},{"description":"Had the planned dose of Intraperitoneal (IP) Paclitaxel (80 IP) but had a dose reduction for intravenous (IV) Paclitaxel (60 IV), and a dose reduction for Nilotinib (400 every day (QD).","id":"OG003","title":"Intravenous Paclitaxel DoseLevel -1, Intraperitoneal Paclitaxel DoseLevel 1, Nilotinib Dose Level -1"}],"paramType":"NUMBER","populationDescription":"7/21 participants were analyzed because 12 participants were not treated and 2 refused further treatment.","reportingStatus":"POSTED","timeFrame":"Baseline, every 9 weeks during treatment, and then every 3 months for 2 years","title":"Clinicopathologic Response to Therapy by Peritoneal Carcinomatosis Index (PCI) Reported for All Participants Along With a 95% Confidence Interval","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}